Pulse Dosing Vismodegib Therapy as an Effective Treatment of Basal Cell Carcinoma: A Case Report
Main Article Content
Keywords
Basal Cell Carcinoma, Sonic hedgehog signaling pathway, Vismodegib
Abstract
Basal cell carcinoma (BCC) is a common nonmelanoma skin cancer, frequently present on the face and head. BCC is linked to the Sonic Hedgehog (Shh) signaling pathway. Mutations within the Shh signaling pathway, involving the activation of the ligand-independent pathway by the Smoothened (Smo) protein, can lead to unregulated proliferation of basal cells, resulting in BCC. Vismodegib, a hedgehog pathway inhibitor, is a chemotherapy drug approved for targeting the Shh signaling pathway. We herein report a presentation of nodular BCC in a Caucasian female who was treated with Vismodegib. This case highlights the effectiveness of pulse dosing treatment to minimize side effects.
References
2. Aditya S, Rattan A. Vismodegib: A smoothened inhibitor for the treatment of advanced basal cell carcinoma. Indian Dermatol Online J. 2013 Oct;4(4):365-8. doi: 10.4103/2229-5178.120685. PMID: 24350028; PMCID: PMC3853913.
3. Nix NM, Burdine O, Walker M. Vismodegib: First-in-Class Hedgehog Pathway Inhibitor for Metastatic or Locally Advanced Basal Cell Carcinoma. J Adv Pract Oncol. 2014 Jul-Aug;5(4):294-6. doi: 10.6004/jadpro.2014.5.4.7. PMID: 26110074; PMCID: PMC4457185.
4. Li X, Sun R, Wu H, Zheng C, Long YQ. Targeting the Hedgehog pathway with novel Gli1 hydrophobic tagging degraders. Bioorg Chem. 2023 Sep;138:106649. doi: 10.1016/j.bioorg.2023.106649. Epub 2023 Jun 7. PMID: 37307715.
5. Suchors C, Kim J. Canonical Hedgehog Pathway and Noncanonical GLI Transcription Factor Activation in Cancer. Cells. 2022 Aug 14;11(16):2523. doi: 10.3390/cells11162523. PMID: 36010600; PMCID: PMC9406872.
6. Koelblinger P, Lang R. New developments in the treatment of basal cell carcinoma: update on current and emerging treatment options with a focus on vismodegib. Onco Targets Ther. 2018 Nov 23;11:8327-8340. doi: 10.2147/OTT.S135650. PMID: 30568456; PMCID: PMC6267762.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.